GSK 2023 Oncology Medical Congress
GSK will be at the American Society of Clinical Oncology (ASCO) annual meeting 2023.
Date: 2-6 June
Location: Chicago, Illinois, US
GSK at Oncology Medical Congress 2023
This June, at the American Society of Clinical Oncology® (ASCO®) annual meeting, we will share 33 data presentations describing new findings and progress in our oncology portfolio and pipeline. The presentations at ASCO will underscore our commitment to maximizing patient survival and improving outcomes by developing transformative medicines for people with blood and gynecologic cancers and other solid tumors.
Our research into new therapeutic approaches that target key pathways and maximize anti-tumor activity drives our strong oncology pipeline and clinical trial program, now with 11 assets in development.
Our therapies utilize immuno-oncology, synthetic lethality, and tumor cell targeting to expand options for patients to improve outcomes and quality of life for people with cancer. We are exploring new treatment approaches that have the potential to address some of the biggest challenges in oncology. Further, we have the leading portfolio of investigational antibodies targeting checkpoints on the CD226 axis, a promising new area of focus for the next generation of immuno-oncology therapies. These checkpoints play a critical role in immune surveillance and can allow cancer cells to evade detection and destruction. By applying this type of selective inhibition, we hope to enhance the immune system’s ability to fight cancer.
If you are a healthcare professional, you can learn more about our marketed products by selecting your market and the specific GSKPro website on our worldwide directory.
Patient stories
Targeting a better future for multiple myeloma patients
GSK is driving progress for the multiple myeloma community by identifying and accelerating innovative solutions. Now in its second year, GSK’s Target the Future Think Tank Challenge awards funding to an individual or group with the most innovative idea to address the unmet needs of people with multiple myeloma. The inaugural grant recipient in 2022 – HealthTree Foundation – is utilizing Target the Future funding and GSK resources to improve access, education, and support for underserved communities and minority patients. This year, we’re targeting disparities presently affecting multiple myeloma care and look forward to supporting ideas to address unmet needs.
We are currently accepting grant applicants for 2023 Think Tank Challenge. Find out more about your eligibility and submit your application at our target the future site.
Learn more about our Target the Future Think Tank Challenge
Target the Future Site
Join our efforts to target a better future for the multiple myeloma community.
Year 1 Winner
GSK selects Target the Future grant recipient in innovation challenge supporting the multiple myeloma community.
Go Behind the Science
Discover how we’re uniting technology, science, and talent to get ahead of cancer and advance a new generation of cancer therapies.
